glp-1 parkinson's disease lancet Frontiers GLP-1 does not slow Parkinson's
Description
1 summarizes the fundamental mechanisms of action of these three hormones
With regards to specific outcomes such as HF, there has been heterogeneity in the results with both GLP-1RAs and DPP-4i
Read the study here
[DOI] [PubMed] [Google Scholar] 154
Oral formulations may attract patients who declined injectable GLP-1s, driving new PA volume that ePA systems must absorb
Wegovy recently also gained approval for the treatment of fatty liver disease (technically called metabolic dysfunction-associated steatohepatitis or MASH) in adults with moderate to advanced liver fibrosis
